Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.82% for the 12-month period ending 2025-03-31, per its 10-K filed 2025-06-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-06-30
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 1.82%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 2.50%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|
| 2025-03-31 | 1.82% 10-K · filed 2025-06-30 | |
| 2022-12-31 | 4.00% 10-Q · filed 2023-02-14 | |
| 2014-03-31 | 2.50% 10-K · filed 2016-06-15 |